Anti-inflammatory effect of 1α,25-dihydroxyvitamin D3 in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease

[1]  Eun-So Lee,et al.  Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet's disease. , 2008, Rheumatology.

[2]  A. Bonanomi,et al.  Vitamin D derivatives induce apoptosis and downregulate ICAM‐1 levels in peripheral blood mononuclear cells of inflammatory bowel disease patients , 2008, Inflammatory bowel diseases.

[3]  P. Menheere,et al.  Vitamin D as an immune modulator in multiple sclerosis, a review , 2008, Journal of Neuroimmunology.

[4]  K. Spach,et al.  1,25‐dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking , 2007, Journal of neuroscience research.

[5]  C. Hemmingsen,et al.  Effect of 1,25-dihydroxy-vitamin D3 in experimental sepsis , 2007, International journal of medical sciences.

[6]  A. Silman,et al.  Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. , 2007, Arthritis and rheumatism.

[7]  A. Douvdevani,et al.  RETRACTED: The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  A. Bonanomi,et al.  The Vitamin D analogue TX 527 blocks NF-κB activation in peripheral blood mononuclear cells of patients with Crohn's disease , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  C. Treves,et al.  1,25‐Dihydroxyvitamin D3 inhibits tumor necrosis factor‐α‐induced adhesion molecule expression in endothelial cells , 2006 .

[10]  J. Adams,et al.  1,25‐Dihydroxyvitamin D3 inhibits lipopolysaccharide‐induced immune activation in human endothelial cells , 2006 .

[11]  T. Ichiyama,et al.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease , 2005, Clinical and experimental immunology.

[12]  S. Nagpal,et al.  Vitamin D receptor modulators for inflammation and cancer. , 2005, Mini reviews in medicinal chemistry.

[13]  Tomio Kobayashi,et al.  Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. , 2003, The Journal of pediatrics.

[14]  J. Newburger,et al.  Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. , 2003, Jornal de Pediatria.

[15]  L. Freedman,et al.  1,25-Dihydroxyvitamin D3 Inhibits IFN-γ and IL-4 Levels During In Vitro Polarization of Primary Murine CD4+ T Cells1 , 2002, The Journal of Immunology.

[16]  Huub F. J. Savelkoul,et al.  1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells1 , 2001, The Journal of Immunology.

[17]  Takashi Ichiyama,et al.  NF-κB Activation in Peripheral Blood Monocytes/Macrophages and T Cells during Acute Kawasaki Disease , 2001 .

[18]  M. Saleem,et al.  Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. , 2000, The Journal of pediatrics.

[19]  D. Sherry,et al.  Initial intravenous gammaglobulin treatment failure in Kawasaki disease. , 2000, Pediatrics.

[20]  G. Meinhardt,et al.  Effects of trovafloxacin on the IL-1-dependent activation of E-selectin in human endothelial cells in vitro. , 2000, Immunopharmacology.

[21]  L. Adorini,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation , 2000, The Journal of Immunology.

[22]  Lukas Wagner,et al.  A Greedy Algorithm for Aligning DNA Sequences , 2000, J. Comput. Biol..

[23]  J. Newburger,et al.  Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. , 1998, The Pediatric infectious disease journal.

[24]  W. Stremmel,et al.  Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. , 1996, The American journal of medicine.

[25]  K Hashino,et al.  Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. , 1996, Circulation.

[26]  L. Freedman,et al.  Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor , 1995, Molecular and cellular biology.

[27]  K. Yabuta,et al.  Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. , 1994, The Journal of pediatrics.

[28]  A. Yachi,et al.  Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease. , 1992, Arthritis and rheumatism.

[29]  M Takahashi,et al.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. , 1991, The New England journal of medicine.

[30]  H. Kato,et al.  Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. , 1988, Clinical immunology and immunopathology.

[31]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[32]  F. Singer,et al.  Pharmacokinetics and biologic effects of calcitriol in normal humans. , 1985, The Journal of laboratory and clinical medicine.

[33]  H. Nakano,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[34]  Katsuko Sato,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[35]  J. Winer,et al.  The effect of renal function on changes in circulating concentrations of 1,25-dihydroxycholecalciferol after an oral dose. , 1982, Clinical science.

[36]  Y. Hamashima,et al.  Pathology of the heart in Kawasaki disease. , 1978, Pediatrics.

[37]  H. Yanagawa,et al.  A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. , 1974, Pediatrics.

[38]  C. Hemmingsen,et al.  Effect of 1,25-dihydroxy-vitamin D 3 in experimental sepsis , 2007 .

[39]  K. Yabuta,et al.  Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-α and interleukin 6 in serum , 2005, European Journal of Pediatrics.

[40]  A. Boonstra,et al.  25-Dihydroxyvitamin D 3 Has a Direct Effect on Naive CD 4 T Cells to Enhance the Development of Th 2 Cells 1 , 2001 .

[41]  小池太郎.  腎性の二次性上皮小体機能亢進症における上皮小体の研究 -1,25-dihydroxyvitamin D[3] receptor密度と細胞増殖能との関係 , 1997 .

[42]  D. Kim,et al.  Serum soluble E-selectin levels in Kawasaki disease. , 1994, Scandinavian journal of rheumatology.